Bone Biology and Osteoporosis: Back to the Basics
Learning Objectives
Who Is at Risk for Osteoporosis?
Most Women With Hip Fractures Do Not Have a T score ≤ -2.5
FRAX
FRAX Clinical Risk Factors
Who Should Be Treated?
RANKL Is Implicated in Bone Loss Across a Broad Range of Conditions
Potential Strategies for Downregulating RANKL
Wnt Signaling Pathway
Inhibition of Sclerostin Stimulates Bone Formation
PTH Inhibits Sclerostin and Stimulates Bone Formation
Inhibition of Cathepsin K Inhibits Bone Resorption
Individualizing Treatment Decisions
Individual Patient Factors
Clinical Challenges After Starting Treatment
Summary
Abbreviations
Abbreviations (cont)
References
References (cont)